Federal award
PATHOVACS INC
W911QY20C0114
ContractSBIR/STTR ST2
Obligated and Ceiling
- Obligated (net)
- $975,605.67
- Ceiling (potential value, not spending)
- $975,605.67
- Current value
- $975,605.67
- Gross positive obligations
- $975,605.67
Obligated is what the government has committed, net of de-obligations. The ceiling is the most the award or vehicle could ever reach; it is shown separately and never added to, or compared as, spending.
Award Details
- Recipient
- PATHOVACS INC · GAEYBFGAB1N9
- Owner company
- Not a reviewed companyNo reviewed company owns this recipient.
- Reported parent
- PATHOVACS INC · GAEYBFGAB1N9
- Awarding agency
- Department of War · sub-agency 2100 · office W911SR
- Funding agency
- Department of War · sub-agency 2100
- Product or service (PSC)
- AD25 · R&D- DEFENSE OTHER: SERVICES (OPERATIONAL SYSTEMS DEVELOPMENT)
- Industry (NAICS)
- 541714 · RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
- PIID
- W911QY20C0114
- Award type code
- D
- Actions
- 10 · Aug 31, 2020 to Mar 13, 2024
- Why it is listed
- gross positive obligations of $100k or more (contracts); SBIR/STTR award
Action History10
| Date | FY | Mod | Action type | Obligation | Company in company totals |
|---|---|---|---|---|---|
| Mar 13, 2024 | FY2024 | P00008 | M | $0.00 | — |
| Mar 13, 2023 | FY2023 | P00007 | M | $0.00 | — |
| Feb 23, 2023 | FY2023 | P00006 | B | $0.00 | — |
| Feb 22, 2023 | FY2023 | A00001 | M | $0.00 | — |
| Aug 1, 2022 | FY2022 | P00005 | B | $0.00 | — |
| Jul 29, 2021 | FY2021 | P00004 | C | $469,366.19 | — |
| Feb 4, 2021 | FY2021 | P00003 | M | $0.00 | — |
| Jan 8, 2021 | FY2021 | P00002 | M | $0.00 | — |
| Oct 29, 2020 | FY2021 | P00001 | M | $0.00 | — |
| Aug 31, 2020 | FY2020 | 0 | — | $506,239.48 | — |
Newest first. Every obligation is shown as reported, including zero and negative (de-obligation) actions. Award lists belong to the company of the latest action; company totals credit each action to the company named on that row, so a note marks rows where the two differ.